1
|
Wang J, Zhao W, Zhang Z, Liu X, Xie T, Wang L, Xue Y, Zhang Y. A Journey of Challenges and Victories: A Bibliometric Worldview of Nanomedicine since the 21st Century. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2024; 36:e2308915. [PMID: 38229552 DOI: 10.1002/adma.202308915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 11/18/2023] [Indexed: 01/18/2024]
Abstract
Nanotechnology profoundly affects the advancement of medicine. Limitations in diagnosing and treating cancer and chronic diseases promote the growth of nanomedicine. However, there are very few analytical and descriptive studies regarding the trajectory of nanomedicine, key research powers, present research landscape, focal investigative points, and future outlooks. Herein, articles and reviews published in the Science Citation Index Expanded of Web of Science Core Collection from first January 2000 to 18th July 2023 are analyzed. Herein, a bibliometric visualization of publication trends, countries/regions, institutions, journals, research categories, themes, references, and keywords is produced and elaborated. Nanomedicine-related academic output is increasing since the COVID-19 pandemic, solidifying the uneven global distribution of research performance. While China leads in terms of publication quantity and has numerous highly productive institutions, the USA has advantages in academic impact, commercialization, and industrial value. Nanomedicine integrates with other disciplines, establishing interdisciplinary platforms, in which drug delivery and nanoparticles remain focal points. Current research focuses on integrating nanomedicine and cell ferroptosis induction in cancer immunotherapy. The keyword "burst testing" identifies promising research directions, including immunogenic cell death, chemodynamic therapy, tumor microenvironment, immunotherapy, and extracellular vesicles. The prospects, major challenges, and barriers to addressing these directions are discussed.
Collapse
Affiliation(s)
- Jingyu Wang
- Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, 100034, China
| | - Wenling Zhao
- Beijing National Laboratory for Molecular Sciences, CAS Laboratory of Colloid and Interface and Thermodynamics CAS Research/Education Center for Excellence in Molecular Sciences, Center for Carbon Neutral Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, China
| | - Zhao Zhang
- Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, 100034, China
| | - Xingzi Liu
- Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, 100034, China
| | - Tong Xie
- Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, 100034, China
| | - Lan Wang
- Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, 100034, China
| | - Yuzhou Xue
- Department of Cardiology, Institute of Vascular Medicine, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, State Key Laboratory of Vascular Homeostasis and Remodeling Peking University, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, 100191, China
| | - Yuemiao Zhang
- Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, 100034, China
| |
Collapse
|
2
|
Zhou B, Ma Y, Li L, Shi X, Chen Z, Wu F, Liu Y, Zhang Z, Wang S. Pheophorbide co-encapsulated with Cisplatin in folate-decorated PLGA nanoparticles to treat nasopharyngeal carcinoma: Combination of chemotherapy and photodynamic therapy. Colloids Surf B Biointerfaces 2021; 208:112100. [PMID: 34547704 DOI: 10.1016/j.colsurfb.2021.112100] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Revised: 08/30/2021] [Accepted: 09/05/2021] [Indexed: 01/09/2023]
Abstract
The adverse effect and drug resistance of Cisplatin (CDDP) could be potential reduced by delivering in targeted nanoparticles and by combining with adjuvant therapy such as photodynamic therapy. In this study, F/CDPR-NP was formulated and characterized for all the physicochemical, biological and in vivo analysis. The results obtained from various in vitro and biological studies showed that encapsulation of CDDP and PBR in PLGA nanoparticles results in controlled release of encapsulated drugs and exhibited significantly low cell viability in CNE-1 and HNE-1 cancer cells. F/CDPR-NP significantly prolonged the blood circulation of the encapsulated drugs. The AUC of CDDP from F/CDPR-NP (4-fold) was significantly higher compared to that of free CDDP and similarly significantly higher t1/2 for CDDP from F/CDPR-NP was observed. F/CDPR-NP in the presence of laser irradiation showed significant reduction in the tumor burden with low tumor cell proliferations compared to either CDPR-NP or free CDDP indicating the potential of targeted nanoparticles and photodynamic therapy. Overall, combination of treatment modalities and active targeting approach paved way for the higher antitumor activity in nasopharyngeal carcinoma model. The positive results from this study will show new horizon for the treatment of other cancer models.
Collapse
Affiliation(s)
- Benzhong Zhou
- Department of Otolaryngology, Head and Neck Surgery, The 901st Hospital of the Joint Logistics Support Force of PLA, Hefei, Anhui 230031, China
| | - Yunxia Ma
- Department of Otolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China
| | - Longqiao Li
- Department of Otolaryngology, Head and Neck Surgery, The 901st Hospital of the Joint Logistics Support Force of PLA, Hefei, Anhui 230031, China
| | - Xianping Shi
- Department of Otolaryngology, Head and Neck Surgery, The 901st Hospital of the Joint Logistics Support Force of PLA, Hefei, Anhui 230031, China
| | - Zhitai Chen
- Department of Otolaryngology, Head and Neck Surgery, The 901st Hospital of the Joint Logistics Support Force of PLA, Hefei, Anhui 230031, China
| | - Feifeng Wu
- Department of Otolaryngology, Head and Neck Surgery, The 901st Hospital of the Joint Logistics Support Force of PLA, Hefei, Anhui 230031, China
| | - Yang Liu
- Department of Otolaryngology, Head and Neck Surgery, The 901st Hospital of the Joint Logistics Support Force of PLA, Hefei, Anhui 230031, China
| | - Zesheng Zhang
- Department of Otolaryngology, Head and Neck Surgery, The 901st Hospital of the Joint Logistics Support Force of PLA, Hefei, Anhui 230031, China
| | - Shengguo Wang
- Department of Otolaryngology, Head and Neck Surgery, The 901st Hospital of the Joint Logistics Support Force of PLA, Hefei, Anhui 230031, China.
| |
Collapse
|
3
|
Friedrich RP, Cicha I, Alexiou C. Iron Oxide Nanoparticles in Regenerative Medicine and Tissue Engineering. NANOMATERIALS 2021; 11:nano11092337. [PMID: 34578651 PMCID: PMC8466586 DOI: 10.3390/nano11092337] [Citation(s) in RCA: 43] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Revised: 09/03/2021] [Accepted: 09/06/2021] [Indexed: 12/13/2022]
Abstract
In recent years, many promising nanotechnological approaches to biomedical research have been developed in order to increase implementation of regenerative medicine and tissue engineering in clinical practice. In the meantime, the use of nanomaterials for the regeneration of diseased or injured tissues is considered advantageous in most areas of medicine. In particular, for the treatment of cardiovascular, osteochondral and neurological defects, but also for the recovery of functions of other organs such as kidney, liver, pancreas, bladder, urethra and for wound healing, nanomaterials are increasingly being developed that serve as scaffolds, mimic the extracellular matrix and promote adhesion or differentiation of cells. This review focuses on the latest developments in regenerative medicine, in which iron oxide nanoparticles (IONPs) play a crucial role for tissue engineering and cell therapy. IONPs are not only enabling the use of non-invasive observation methods to monitor the therapy, but can also accelerate and enhance regeneration, either thanks to their inherent magnetic properties or by functionalization with bioactive or therapeutic compounds, such as drugs, enzymes and growth factors. In addition, the presence of magnetic fields can direct IONP-labeled cells specifically to the site of action or induce cell differentiation into a specific cell type through mechanotransduction.
Collapse
|
4
|
Márquez AB, van der Vorst EPC, Maas SL. Key Chemokine Pathways in Atherosclerosis and Their Therapeutic Potential. J Clin Med 2021; 10:3825. [PMID: 34501271 PMCID: PMC8432216 DOI: 10.3390/jcm10173825] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Revised: 08/20/2021] [Accepted: 08/20/2021] [Indexed: 12/24/2022] Open
Abstract
The search to improve therapies to prevent or treat cardiovascular diseases (CVDs) rages on, as CVDs remain a leading cause of death worldwide. Here, the main cause of CVDs, atherosclerosis, and its prevention, take center stage. Chemokines and their receptors have long been known to play an important role in the pathophysiological development of atherosclerosis. Their role extends from the initiation to the progression, and even the potential regression of atherosclerotic lesions. These important regulators in atherosclerosis are therefore an obvious target in the development of therapeutic strategies. A plethora of preclinical studies have assessed various possibilities for targeting chemokine signaling via various approaches, including competitive ligands and microRNAs, which have shown promising results in ameliorating atherosclerosis. Developments in the field also include detailed imaging with tracers that target specific chemokine receptors. Lastly, clinical trials revealed the potential of various therapies but still require further investigation before commencing clinical use. Although there is still a lot to be learned and investigated, it is clear that chemokines and their receptors present attractive yet extremely complex therapeutic targets. Therefore, this review will serve to provide a general overview of the connection between various chemokines and their receptors with atherosclerosis. The different developments, including mouse models and clinical trials that tackle this complex interplay will also be explored.
Collapse
Affiliation(s)
- Andrea Bonnin Márquez
- Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, 52074 Aachen, Germany;
- Interdisciplinary Center for Clinical Research (IZKF), RWTH Aachen University, 52074 Aachen, Germany
- Department of Pathology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, 6229 ER Maastricht, The Netherlands
| | - Emiel P. C. van der Vorst
- Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, 52074 Aachen, Germany;
- Interdisciplinary Center for Clinical Research (IZKF), RWTH Aachen University, 52074 Aachen, Germany
- Department of Pathology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, 6229 ER Maastricht, The Netherlands
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich, 80336 Munich, Germany
- German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, 80336 Munich, Germany
| | - Sanne L. Maas
- Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, 52074 Aachen, Germany;
- Interdisciplinary Center for Clinical Research (IZKF), RWTH Aachen University, 52074 Aachen, Germany
| |
Collapse
|
5
|
Evans RJ, Lavin B, Phinikaridou A, Chooi KY, Mohri Z, Wong E, Boyle JJ, Krams R, Botnar R, Long NJ. Targeted Molecular Iron Oxide Contrast Agents for Imaging Atherosclerotic Plaque. Nanotheranostics 2020; 4:184-194. [PMID: 32637296 PMCID: PMC7332796 DOI: 10.7150/ntno.44712] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Accepted: 05/06/2020] [Indexed: 02/03/2023] Open
Abstract
Overview: Cardiovascular disease remains a leading cause of death worldwide, with vulnerable plaque rupture the underlying cause of many heart attacks and strokes. Much research is focused on identifying an imaging biomarker to differentiate stable and vulnerable plaque. Magnetic Resonance Imaging (MRI) is a non-ionising and non-invasive imaging modality with excellent soft tissue contrast. However, MRI has relatively low sensitivity (micromolar) for contrast agent detection compared to nuclear imaging techniques. There is also an increasing emphasis on developing MRI probes that are not based on gadolinium chelates because of increasing concerns over associated systemic toxicity and deposits1. To address the sensitivity and safety concerns of gadolinium this project focused on the development of a high relaxivity probe based on superparamagnetic iron oxide nanoparticles for the imaging of atherosclerotic plaque with MRI. With development, this may facilitate differentiating stable and vulnerable plaque in vivo. Aim: To develop a range of MRI contrast agents based on superparamagnetic iron oxide nanoparticles (SPIONs), and test them in a murine model of advanced atherosclerosis. Methods: Nanoparticles of four core sizes were synthesised by thermal decomposition and coated with poly(maleicanhydride-alt-1-octadecene) (PMAO), poly(ethyleneimine) (PEI) or alendronate, then characterised for core size, hydrodynamic size, surface potential and relaxivity. On the basis of these results, one candidate was selected for further studies. In vivo studies using 10 nm PMAO-coated SPIONs were performed in ApoE-/- mice fed a western diet and instrumented with a perivascular cuff on the left carotid artery. Control ApoE-/- mice were fed a normal chow diet and were not instrumented. Mice were scanned on a 3T MR scanner (Philips Achieva) with the novel SPION contrast agent, and an elastin-targeted gadolinium agent that was shown previously to enable visualisation of plaque burden. Histological analysis was undertaken to confirm imaging findings through staining for macrophages, CX3CL1, elastin, tropoelastin, and iron. Results: The lead SPION agent consisted of a 10 nm iron oxide core with poly(maleicanhydride-alt-1-octadecene), (-36.21 mV, r2 18.806 mmol-1/s-1). The irregular faceting of the iron oxide core resulted in high relaxivity and the PMAO provided a foundation for further functionalisation on surface -COOH groups. The properties of the contrast agent, including the negative surface charge and hydrodynamic size, were designed to maximise circulation time and evade rapid clearance through the renal system or phagocytosis. In vitro testing showed that the SPION agent was non-toxic. In vivo results show that the novel contrast agent accumulates in similar vascular regions to a gadolinium-based contrast agent (Gd-ESMA) targeted to elastin, which accumulates in plaque. There was a significant difference in SPION signal between the instrumented and the contralateral non-instrumented vessels in diseased mice (p = 0.0411, student's t-test), and between the instrumented diseased vessel and control vessels (p = 0.0043, 0.0022, student's t-test). There was no significant difference between the uptake of either contrast agent between stable and vulnerable plaques (p = 0.3225, student's t-test). Histological verification was used to identify plaques, and Berlin Blue staining confirmed the presence of nanoparticle deposits within vulnerable plaques and co-localisation with macrophages. Conclusion: This work presents a new MRI contrast agent for atherosclerosis which uses an under-explored surface ligand, demonstrating promising properties for in vivo behaviour, is still in circulation 24 hours post-injection with limited liver uptake, and shows good accumulation in a murine plaque model.
Collapse
Affiliation(s)
- Rhiannon J Evans
- Department of Chemistry, MSRH Building, Imperial College London, White City Campus, 80 Wood Lane, White City, London, W12 0BZ, UK.,School of Biomedical Engineering and Imaging Science, St. Thomas's Hospital, King's College London, London, SE1 7EH, UK
| | - Begoña Lavin
- School of Biomedical Engineering and Imaging Science, St. Thomas's Hospital, King's College London, London, SE1 7EH, UK
| | - Alkystis Phinikaridou
- School of Biomedical Engineering and Imaging Science, St. Thomas's Hospital, King's College London, London, SE1 7EH, UK
| | - Kok Yean Chooi
- Department of Bioengineering, Imperial College London, South Kensington, London, SW7 2AZ, UK
| | - Zahra Mohri
- Department of Bioengineering, Imperial College London, South Kensington, London, SW7 2AZ, UK
| | - Eunice Wong
- Department of Chemistry, MSRH Building, Imperial College London, White City Campus, 80 Wood Lane, White City, London, W12 0BZ, UK.,National Heart and Lung Institute, ICTEM Building, Imperial College London, Hammersmith Campus, Du Cane Rd, London, W12 0NN, UK
| | - Joseph J Boyle
- National Heart and Lung Institute, ICTEM Building, Imperial College London, Hammersmith Campus, Du Cane Rd, London, W12 0NN, UK
| | - Rob Krams
- Department of Bioengineering, Imperial College London, South Kensington, London, SW7 2AZ, UK
| | - René Botnar
- School of Biomedical Engineering and Imaging Science, St. Thomas's Hospital, King's College London, London, SE1 7EH, UK
| | - Nicholas J Long
- Department of Chemistry, MSRH Building, Imperial College London, White City Campus, 80 Wood Lane, White City, London, W12 0BZ, UK
| |
Collapse
|
6
|
Brusini R, Dormont F, Cailleau C, Nicolas V, Peramo A, Varna M, Couvreur P. Squalene-based nanoparticles for the targeting of atherosclerotic lesions. Int J Pharm 2020; 581:119282. [PMID: 32259640 DOI: 10.1016/j.ijpharm.2020.119282] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2020] [Revised: 03/25/2020] [Accepted: 03/26/2020] [Indexed: 12/17/2022]
Abstract
Native low-density lipoproteins (LDL) naturally accumulate at atherosclerotic lesions and are thought to be among the main drivers of atherosclerosis progression. Numerous nanoparticular systems making use of recombinant lipoproteins have been developed for targeting atherosclerotic plaque. These innovative formulations often require complicated purification and synthesis procedures which limit their eventual translation to the clinics. Recently, squalenoylation has appeared as a simple and efficient technique for targeting agents to endogenous lipoproteins through a bioconjugation approach. In this study, we have developed a fluorescent squalene bioconjugate to evaluate the biodistribution of squalene-based nanoparticles in an ApoE-/- model of atherosclerosis. By accumulating in LDL endogenous nanoparticles, the squalene bioconjugation could serve as an efficient targeting platform for atherosclerosis. Indeed, in this proof of concept, we show that our squalene-rhodamine (SQRho) nanoparticles, could accumulate in the aortas of atherosclerotic animals. Histological evaluation confirmed the presence of atherosclerotic lesions and the co-localization of SQRho bioconjugates at the lesion sites.
Collapse
Affiliation(s)
- Romain Brusini
- Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92290 Châtenay-Malabry, France
| | - Flavio Dormont
- Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92290 Châtenay-Malabry, France
| | - Catherine Cailleau
- Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92290 Châtenay-Malabry, France
| | - Valerie Nicolas
- IPSIT, Microscopy Facility, University of Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France
| | - Arnaud Peramo
- Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92290 Châtenay-Malabry, France
| | - Mariana Varna
- Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92290 Châtenay-Malabry, France
| | - Patrick Couvreur
- Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92290 Châtenay-Malabry, France.
| |
Collapse
|
7
|
Antunes JC, Benarroch L, Moraes FC, Juenet M, Gross MS, Aubart M, Boileau C, Caligiuri G, Nicoletti A, Ollivier V, Chaubet F, Letourneur D, Chauvierre C. Core-Shell Polymer-Based Nanoparticles Deliver miR-155-5p to Endothelial Cells. MOLECULAR THERAPY. NUCLEIC ACIDS 2019; 17:210-222. [PMID: 31265949 PMCID: PMC6610682 DOI: 10.1016/j.omtn.2019.05.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Revised: 05/20/2019] [Accepted: 05/20/2019] [Indexed: 12/12/2022]
Abstract
Heart failure occurs in over 30% of the worldwide population and most commonly originates from cardiovascular diseases such as myocardial infarction. microRNAs (miRNAs) target and silence specific mRNAs, thereby regulating gene expression. Because the endogenous miR-155-5p has been ascribed to vasculoprotection, loading it onto positively charged, core-shell poly(isobutylcyanoacrylate) (PIBCA)-polysaccharide nanoparticles (NPs) was attempted. NPs showed a decrease (p < 0.0001) in surface electrical charge (ζ potential), with negligible changes in size or shape when loaded with the anionic miR-155-5p. Presence of miR-155-5p in loaded NPs was further quantified. Cytocompatibility up to 100 μg/mL of NPs for 2 days with human coronary artery endothelial cells (hCAECs) was documented. NPs were able to enter hCAECs and were localized in the endoplasmic reticulum (ER). Expression of miR-155-5p was increased within the cells by 75-fold after 4 hours of incubation (p < 0.05) and was still noticeable at day 2. Differences between loaded NP-cultured cells and free miRNA, at days 1 (p < 0.05) and 2 (p < 0.001) suggest the ability of prolonged load release in physiological conditions. Expression of miR-155-5p downstream target BACH1 was decreased in the cells by 4-fold after 1 day of incubation (p < 0.05). This study is a first proof of concept that miR-155-5p can be loaded onto NPs and remain intact and biologically active in endothelial cells (ECs). These nanosystems could potentially increase an endogenous cytoprotective response and decrease damage within infarcted hearts.
Collapse
Affiliation(s)
- Joana C Antunes
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Louise Benarroch
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Fernanda C Moraes
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Maya Juenet
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Marie-Sylvie Gross
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Mélodie Aubart
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Catherine Boileau
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Giuseppina Caligiuri
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Antonino Nicoletti
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Véronique Ollivier
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Frédéric Chaubet
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Didier Letourneur
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Cédric Chauvierre
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
| |
Collapse
|
8
|
Son J, Yang SM, Yi G, Roh YJ, Park H, Park JM, Choi MG, Koo H. Folate-modified PLGA nanoparticles for tumor-targeted delivery of pheophorbide a in vivo. Biochem Biophys Res Commun 2018. [PMID: 29518390 DOI: 10.1016/j.bbrc.2018.03.013] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Targeted drug delivery has been an important issue for tumor therapy including photodynamic therapy (PDT). The purpose of our study is to increase the targeting efficiency of photosensitizer (PS) using folate-modified nanoparticles (NPs) to tumor site in vivo. Folate receptor is over-expressed on the surface of many human cancer cells. We prepared poly (lactic-co-glycolic acid) (PLGA) NPs containing pheophorbide a (Pba), a PS that is used in PDT and generates free radical for killing cancer cells. The surface of NPs was composed of phospholipids modified with polyethylene glycol (PEG) and folate (FA). The size of the resulting FA-PLGA-Pba NPs was about 200 nm in PBS at pH 7.4 and they were stable for long time. They showed faster cellular uptake to MKN28 human gastric cancer cell line than control PLGA-Pba NPs by high-affinity binding with folate receptors on cell surface. In MTT assay, FA-PLGA-Pba NPs also showed enhanced tumor cell killing compared to control PLGA-Pba NPs. In vivo and ex vivo imaging showed high accumulation of FA-PLGA-Pba NPs in tumor site during 24 h after intravenous injection to MKN28 tumor-bearing mice model. These results demonstrate that our FA-PLGA-Pba NPs are useful for tumor-targeted delivery of PS for cancer treatment by PDT.
Collapse
Affiliation(s)
- Jihwan Son
- Department of Medical Lifescience, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Seung Mok Yang
- Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
| | - Gawon Yi
- Department of Medical Lifescience, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Yoon Jin Roh
- Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
| | - Hyeji Park
- Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
| | - Jae Myung Park
- Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea; Catholic Photomedicine Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Myung-Gyu Choi
- Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea; Catholic Photomedicine Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Heebeom Koo
- Department of Medical Lifescience, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Catholic Photomedicine Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
| |
Collapse
|
9
|
Varna M, Xuan HV, Fort E. Gold nanoparticles in cardiovascular imaging. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2017; 10. [DOI: 10.1002/wnan.1470] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/11/2016] [Revised: 02/01/2017] [Accepted: 02/25/2017] [Indexed: 01/12/2023]
Affiliation(s)
- Mariana Varna
- Institut LangevinESPCI Paris, CNRS, PSL Research UniversityParisFrance
- Institut Galien Paris‐Sud UMR 8612, CNRSUniversité Paris‐Sud/Paris‐Saclay Faculté de PharmacieChâtenay‐MalabryFrance
| | - Hoa V. Xuan
- Institut LangevinESPCI Paris, CNRS, PSL Research UniversityParisFrance
- Faculty of Physics and TechnologyThai Nguyen University of Science (TNUS)Thai NguyenVietnam
| | - Emmanuel Fort
- Institut LangevinESPCI Paris, CNRS, PSL Research UniversityParisFrance
| |
Collapse
|
10
|
Chauvierre C, Letourneur D. The European project NanoAthero to fight cardiovascular diseases using nanotechnologies. Nanomedicine (Lond) 2016; 10:3391-400. [PMID: 26582278 DOI: 10.2217/nnm.15.170] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Cardiovascular diseases are the main causes of death in the world. Nanosystems with contrast agents or drugs appear as promising tools for early detection and treatments. NanoAthero, a large-scale 5-year project funded by the European Union FP7 gathers 16 partners from ten different countries to demonstrate the benefit of the use of nanoparticle technologies. Through the design and characterization of nanosystems, preclinical and clinical validations, toxicology, industrial development and production in good manufacturing practice forms, several studies are underway for plaque and stroke both for imaging and treatment. A clinical study was already completed using a good manufacturing practice liposomal formulation in patients with carotid atheroma. NanoAthero is a unique opportunity to open new strategies for the management of cardiovascular diseases.
Collapse
Affiliation(s)
- Cédric Chauvierre
- Inserm, U1148, Department of Cardiovascular Bio-Engineering, X Bichat Hospital, University Paris Diderot, 46 rue H Huchard, 75018 Paris, France.,Institut Galilée, University Paris 13, Sorbonne Paris Cité, 93430 Villetaneuse, France
| | - Didier Letourneur
- Inserm, U1148, Department of Cardiovascular Bio-Engineering, X Bichat Hospital, University Paris Diderot, 46 rue H Huchard, 75018 Paris, France.,Institut Galilée, University Paris 13, Sorbonne Paris Cité, 93430 Villetaneuse, France
| |
Collapse
|
11
|
Ananikov VP, Galkin KI, Egorov MP, Sakharov AM, Zlotin SG, Redina EA, Isaeva VI, Kustov LM, Gening ML, Nifantiev NE. Challenges in the development of organic and hybrid molecular systems. MENDELEEV COMMUNICATIONS 2016. [DOI: 10.1016/j.mencom.2016.09.001] [Citation(s) in RCA: 86] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Alexiou C, Fadeel B. Editorial: Brave new world – Focus on nanomedicine. Biochem Biophys Res Commun 2015; 468:409-10. [DOI: 10.1016/j.bbrc.2015.10.135] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|